Pricing Log in Create free account
Friday 6 November 2026 Export MANE’s income statement to Excel — free account

Veradermics Incorporated

MANE Healthcare Biotechnology

138.19 9.59 +7.46%
Market cap
$5.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Veradermics Incorporated 10-Q filed Aug 11, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:38 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 12, 2026: 16 added · 2 removed · 15 modified; 9 with only figures updated

  1. Modified · Overview

    nIn May 2026, we completed ncompletion of our underwritten public offering, or the Follow-On Public Offering, of 4,420,358 shares of our common stock, par value $0.00001 per share, or Common Stock,pursuant to which we issued and sold an aggregate of 4,420,358 shares of common stock at a public offering price of $100.00 per share, including 576,568 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares. The gross proceeds from the Follow-On Public Offering were approximately $442.0 millionWe received aggregate net proceeds of $414.3 million after deducting underwriting discounts, commissions and offering expenses.